TALAPRO-2 trial

The TALAPRO-2 trial is a clinical study testing a new combination therapy for men with advanced prostate cancer that has spread but still responds to hormone treatments. Researchers are evaluating whether adding a drug called talazoparib to standard hormone therapy improves treatment outcomes. The goal is to see if this combination can better delay cancer progression and improve survival compared to hormone therapy alone. This trial helps determine if the new approach offers benefits with manageable side effects, potentially leading to more effective treatment options for patients with this type of prostate cancer.